Cidara Therapeutics Inc (CDTX)
20.40
+2.95
(+16.91%)
USD |
NASDAQ |
Nov 22, 16:00
21.31
+0.91
(+4.46%)
After-Hours: 20:00
Cidara Therapeutics Cash from Financing (Quarterly): -0.182M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.182M |
| June 30, 2024 | 239.13M |
| March 31, 2024 | -0.093M |
| December 31, 2023 | 0.008M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -0.261M |
| March 31, 2023 | 26.24M |
| December 31, 2022 | 0.664M |
| September 30, 2022 | 0.107M |
| June 30, 2022 | -1.111M |
| March 31, 2022 | -0.611M |
| December 31, 2021 | 36.88M |
| September 30, 2021 | -0.81M |
| June 30, 2021 | 0.887M |
| March 31, 2021 | 7.645M |
| December 31, 2020 | 0.409M |
| September 30, 2020 | 3.72M |
| June 30, 2020 | 3.939M |
| March 31, 2020 | 29.21M |
| December 31, 2019 | 1.641M |
| September 30, 2019 | 12.63M |
| June 30, 2019 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2019 | 0.00 |
| December 31, 2018 | -0.012M |
| September 30, 2018 | -2.078M |
| June 30, 2018 | 51.78M |
| March 31, 2018 | 6.468M |
| December 31, 2017 | 20.81M |
| September 30, 2017 | 0.003M |
| June 30, 2017 | 0.005M |
| March 31, 2017 | 0.065M |
| December 31, 2016 | 37.08M |
| September 30, 2016 | -0.057M |
| June 30, 2016 | 0.025M |
| March 31, 2016 | 0.041M |
| December 31, 2015 | 0.271M |
| September 30, 2015 | -0.038M |
| June 30, 2015 | 70.17M |
| March 31, 2015 | 41.41M |
| December 31, 2014 | 0.546M |
| September 30, 2014 | -0.048M |
| June 30, 2014 | 29.87M |
| March 31, 2014 | 0.94M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.111M
Minimum
Jun 2022
239.13M
Maximum
Jun 2024
17.37M
Average
0.5365M
Median
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| Arbutus Biopharma Corp | 1.775M |
| GlycoMimetics Inc | 0.00 |
| FibroGen Inc | -0.127M |
| Cue Biopharma Inc | 9.821M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -36.70M |
| Cash from Investing (Quarterly) | -0.106M |
| Free Cash Flow | -160.15M |
| Free Cash Flow Per Share (Quarterly) | -5.636 |
| Free Cash Flow Yield | -155.8% |